Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.73 |
| ▸ | DRD1 | P21728 | 2/20 | 0.73 |
| ▸ | DRD4 | P21917 | 2/20 | 0.73 |
| ▸ | DRD5 | P21918 | 2/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 2/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | THPO | P40225 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL29456593 | 1.00 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL29435413 | 0.88 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL50427 | 0.88 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL29599861 | 0.86 | MAPT (0.74) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL30379944 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL496657 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL9166387 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL8505 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL29362033 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL18159501 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4065 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130316-A1 | COMPOSITION FOR PREVENTING AND/OR TREATING METABOLIC DISORDERS AND METHOD OF ITS PREPARATION | PHARMAKO BIOTECHNOLOGIES PTY LTD (AU) | 2024-06-27 | — | — | WO | claimed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | claimed |
| US-20240165101-A1 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS FOR SLOWING OF PARKINSON'S DISEASE PROGRESSION | ELI LILLY AND COMPANY | 2024-05-23 | — | — | US | claimed |
| WO-2024088285-A1 | MESYLATE OF HETEROCYCLIC SUBSTITUTED FUSED γ-CARBOLINE DERIVATIVE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海枢境生物科技有限公司 | 2024-05-02 | — | — | WO | claimed |
| CN-117924288-A | Hydrochloride and crystal form of heterocycle substituted condensed gamma-carboline derivative, and preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117924287-A | Salt and crystal form of heterocycle substituted condensed gamma-carboline derivative, and preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| EP-4304581-A1 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS IN THE TREATMENT OF HALLUCINATIONS AND DEMENTIA-RELATED PSYCHOSIS | ELI LILLY AND CO. (US) | 2024-01-17 | — | — | EP | claimed |
| EP-4304577-A1 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS FOR SLOWING OF PARKINSON'S DISEASE PROGRESSION | ELI LILLY AND CO. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117377470-A | Use of mevidaline and other D1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychoses | 伊莱利利公司 | 2024-01-09 | — | — | CN | claimed |
| CN-117337173-A | Use of mevidaline and other D1 positive allosteric modulators for slowing the progression of parkinson's disease | 伊莱利利公司 | 2024-01-02 | — | — | CN | claimed |
| WO-1996037226-A2 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER INC. (US) | 1996-11-28 | — | — | WO | claimed |
| US-5512562-A | FOR CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOSIS, DEPRESSION, SLEEP DISORDERS, PARKINSON*S DISEASE, STROKE | NOVO NORDISK A/S (DK) | 1996-04-30 | — | — | US | claimed |
| WO-1996006856-A1 | DOPAMINE RECEPTOR PEPTIDES AND ANTI-PEPTIDE ANTIBODIES | WEBBER ROBERT (US) | 1996-03-07 | — | — | WO | claimed |
| EP-0347672-B1 | Benzazepine derivatives | NOVO NORDISK AS (DK) | 1994-03-02 | — | — | EP | claimed |
| EP-0538395-A1 | NUCLEIC ACID SEQUENCES ENCODING A HUMAN DOPAMINE D 1? RECEPTOR | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992000986-A1 | NUCLEIC ACID SEQUENCES ENCODING A HUMAN DOPAMINE D1 RECEPTOR | NEUROGENETIC CORPORATION (US) | 1992-01-23 | — | — | WO | claimed |
| US-5025009-A | Treatment of central nervous system disorders; bioavailability | NOVO NORDISK A/S (DK) | 1991-06-18 | — | — | US | claimed |
| US-5010074-A | Treating CNS disorders; dopamine antagonist; bioavailability | NOVO NORDISK A/S (DK) | 1991-04-23 | — | — | US | claimed |
| EP-0347672-A1 | Benzazepine derivatives | NOVO NORDISK A/S (DK) | 1989-12-27 | — | — | EP | claimed |
| US-4855306-A | FOR TREATMENT OF DEGENERATIVE DEMENTIA, DEPRESSION, ANXIETY, OBESITY AND SCHIZOPHRENIA | SANDOZ LTD. (CH) | 1989-08-08 | — | — | US | claimed |